39.12
-2.35
(-5.67%)
At close: 4:00:02 PM EDT
39.12
0.00
(0.00%)
After hours: 4:05:07 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | -0.27 | -0.23 | -0.81 | -0.37 |
| Low Estimate | -0.44 | -0.34 | -1.4 | -1.62 |
| High Estimate | -0.08 | -0.03 | -0.01 | 0.3 |
| Year Ago EPS | -0.54 | -0.52 | -1.85 | -0.81 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 8 |
| Avg. Estimate | 98.4M | 103.56M | 427.77M | 514.5M |
| Low Estimate | 94.39M | 98.18M | 411.17M | 450M |
| High Estimate | 101.79M | 105.6M | 439.9M | 567.86M |
| Year Ago Sales | 69.22M | 77.88M | 336.89M | 427.77M |
| Sales Growth (year/est) | 42.15% | 32.98% | 26.98% | 20.27% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.3 | -0.46 | -0.45 | -0.25 |
| EPS Actual | -0.54 | -0.52 | -0.3 | -0.49 |
| Difference | -0.24 | -0.06 | 0.15 | -0.24 |
| Surprise % | -77.26% | -12.25% | 33.04% | -98.72% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.27 | -0.23 | -0.81 | -0.37 |
| 7 Days Ago | -0.26 | -0.23 | -0.84 | -0.39 |
| 30 Days Ago | -0.26 | -0.23 | -0.84 | -0.39 |
| 60 Days Ago | -0.26 | -0.16 | -0.52 | 1.5 |
| 90 Days Ago | -0.31 | -0.21 | -0.69 | 0.95 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | 1 | -- | 1 | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| MIRM | 49.35% | 55.46% | 55.96% | 54.25% |
| S&P 500 | 6.43% | 6.13% | 9.43% | 14.26% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2025 |
| Maintains | Baird: Outperform to Outperform | 2/27/2025 |
| Reiterates | Citizens Capital Markets: Market Outperform to Market Outperform | 2/24/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2024 |
| Maintains | Citigroup: Buy to Buy | 11/13/2024 |
| Maintains | Baird: Outperform to Outperform | 11/13/2024 |
Related Tickers
BPMC Blueprint Medicines Corporation
80.27
-2.17%
VERA Vera Therapeutics, Inc.
21.81
-0.95%
CGEM Cullinan Therapeutics, Inc.
7.58
-2.70%
RARE Ultragenyx Pharmaceutical Inc.
33.16
-2.21%
CRNX Crinetics Pharmaceuticals, Inc.
26.85
-2.93%
MLTX MoonLake Immunotherapeutics
33.97
-5.59%
NUVL Nuvalent, Inc.
61.99
-4.19%
MRUS Merus N.V.
38.62
-2.38%
PTGX Protagonist Therapeutics, Inc.
40.89
-3.95%
IDYA IDEAYA Biosciences, Inc.
15.77
-0.06%